首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 基因療法

市場調查報告書

商品編碼

1890963

地中海貧血市場按類型、治療方法、最終用戶、給藥途徑、分銷管道、年齡層和地區分類

Thalassemia Market, By Type, By Treatment Type, By End User, By Route of Administration, By Distribution Channel, By Age Group, By Geography

出版日期: 2025年11月12日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，地中海貧血市場在 2025 年的價值為 9.895 億美元，預計到 2032 年將達到 16.848 億美元，2025 年至 2032 年的複合年成長率為 7.9%。

報告覆蓋範圍		報告詳情
基準年：	2024	2025年市場規模：	9.895億美元
歷史數據時期：	2020-2024	預測期：	2025-2032
預測期間（2025-2032年）：	7.90%	預計2032年價值：	16.848億美元

地中海貧血是一組以血紅素合成缺陷為特徵的遺傳性血液疾病，是影響全球數百萬患者的重大全球健康挑戰。這些遺傳性疾病主要流行於地中海地區、東南亞、非洲和中東，導致α或BETA珠蛋白鏈生成減少或缺失，進而引發慢性貧血、器官損傷，並給醫療系統帶來沉重負擔。

全球地中海貧血市場涵蓋一個完整的生態系統，旨在滿足地中海貧血患者複雜的醫療需求，包括診斷工具、治療性介入、輸血服務、鐵螯合療法以及新興基因療法。近年來，人們對基因篩檢的日益關注、產前診斷技術的進步以及CRISPR-Cas9等基因編輯技術的創新發展，推動了該市場前所未有的變革。患者數量的成長、開發中國家醫療保健支出的增加以及研發領域的巨額投資，持續推動市場擴張。此外，人工智慧在藥物研發中的應用、個人化醫療方法以及製藥公司與研究機構之間的合作，正在重塑治療模式，並在全球地中海貧血市場格局中創造新的商機。

市場動態

全球地中海貧血市場的成長受到多個強勁促進因素的支撐。其中包括地中海貧血症在全球日益普遍，尤其是在流行地區，近親結婚和遺傳易感性是導致高發病率的主要原因。基因治療領域的技術進步，例如Zynteglo（Betibegrogen Autotemcel）和其他最先進治療的研發，代表著創新的治療方法，旨在解決疾病的根本原因，而不是僅僅控制症狀。新興經濟體醫療基礎設施的擴張、政府對罕見疾病管理措施的加強，以及對孤兒藥研發的大量投入，都持續推動市場成長。此外，人們對遺傳諮詢、產前篩檢和早期診斷的認知不斷提高，也透過識別需要即時介入的患者，顯著促進了市場擴張。

然而，該市場面臨著許多限制因素，例如基因療法等先進治療方法的高昂費用，每位患者的治療費用可能超過280萬美元，這給中低收入國家的患者造成了就醫障礙。此外，創新治療方法的複雜監管核准流程、專業醫療設施的匱乏以及訓練有素的血液科醫生短缺也是重大挑戰。篩檢地區對基因檢測和創業投資的文化和宗教障礙進一步阻礙了市場滲透。儘管存在這些挑戰，但隨著大型製藥和生物技術公司之間研究合作的加強、基於CRISPR的基因編輯技術的應用不斷擴展以及風險投資對罕見疾病治療日益成長的興趣，市場正在湧現出巨大的機會。更經濟實惠的治療方法方案的開發、罕見疾病醫療覆蓋範圍的擴大以及在開發中國家建立專門的地中海貧血中心，都為市場相關人員帶來了可觀的成長前景。

本次調查的主要特點

本報告以 2024 年為基準年，對全球地中海貧血市場進行了詳細分析，並給出了預測期（2025-2032 年）的市場規模和復合年成長率（%）。
識別各細分市場的潛在商機，並說明該市場具有吸引力的投資提案矩陣。
該研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與企業。
本研究根據以下參數對全球地中海貧血市場的主要企業進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
本報告的研究結果將使負責人和企業經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
這份全球地中海貧血市場報告的目標受眾是該行業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過全球地中海貧血市場分析中使用的各種策略矩陣輕鬆做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第11章競爭格局

bluebird bio Inc.
Bristol Myers Squibb Company
Novartis AG
Chiesi Farmaceutici SpA
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics AG
Acceleron Pharma Inc.
Ionis Pharmaceuticals Inc.
Natco Pharma
Silence Therapeutics plc
Apotex Inc.
Cipla Limited
Sun Pharmaceutical Industries Ltd
Reddy's Laboratories Ltd
Teva Pharmaceutical Industries Ltd

第12章分析師建議

機會
一致的機會地圖

第13章參考文獻與調查方法

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI8913

Thalassemia Market is estimated to be valued at USD 989.5 Mn in 2025 and is expected to reach USD 1,684.8 Mn by 2032, growing at a compound annual growth rate (CAGR) of 7.9% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 989.5 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	7.90%	2032 Value Projection:	USD 1,684.8 Mn

Thalassemia represents a significant global health challenge, constituting a group of inherited blood disorders characterized by defective hemoglobin synthesis that affects millions of individuals worldwide. This genetic condition, predominantly prevalent in Mediterranean regions, Southeast Asia, Africa, and the Middle East, results in reduced or absent production of alpha or beta globin chains, leading to chronic anemia, organ damage, and substantial healthcare burden.

The global thalassemia market encompasses a comprehensive ecosystem of diagnostic tools, therapeutic interventions, blood transfusion services, iron chelation therapies, and emerging gene therapies that collectively address the complex medical needs of thalassemia patients. With increasing awareness about genetic screening, advances in prenatal diagnosis, and revolutionary developments in gene editing technologies like CRISPR-Cas9, the market has witnessed unprecedented transformation in recent years. The growing patient population, coupled with rising healthcare expenditure in developing nations and significant investments in research and development activities, continues to drive market expansion. Additionally, the integration of artificial intelligence in drug discovery, personalized medicine approaches, and collaborative efforts between pharmaceutical companies and research institutions are reshaping treatment paradigms and creating new revenue opportunities across the global thalassemia market landscape.

Market Dynamics

The global thalassemia market is propelled by several compelling drivers, including the increasing prevalence of thalassemia disorders worldwide, particularly in endemic regions where consanguineous marriages and genetic predisposition contribute to higher incidence rates. Technological advancements in gene therapy, such as the development of Zynteglo (betibeglogene autotemcel) and other cutting-edge treatments, represent revolutionary therapeutic approaches that address the root cause of the disease rather than managing symptoms. Growing healthcare infrastructure in emerging economies, coupled with increased government initiatives for rare disease management and substantial funding for orphan drug development, continues to fuel market growth. Rising awareness about genetic counseling, prenatal screening programs, and early diagnosis significantly contribute to market expansion by identifying patients who require immediate intervention.

However, the market faces considerable restraints, including the extremely high cost of advanced therapies like gene therapy, which can exceed US$ 2.8 million per patient, creating accessibility barriers for patients in low and middle-income countries. Complex regulatory approval processes for innovative treatments, limited availability of specialized healthcare facilities, and shortage of trained hematologists pose significant challenges. Cultural and religious barriers in certain regions regarding genetic testing and prenatal screening further impede market penetration. Despite these challenges, substantial opportunities emerge through increasing research collaborations between pharmaceutical giants and biotechnology companies, expanding applications of CRISPR-based gene editing technologies, and growing interest from venture capital firms in rare disease therapeutics. The development of more affordable treatment alternatives, expansion of healthcare insurance coverage for rare diseases, and establishment of specialized thalassemia centers in developing countries present lucrative growth prospects for market stakeholders.

Key Features of the Study

This report provides in-depth analysis of the global thalassemia market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global thalassemia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include bluebird bio Inc., Bristol Myers Squibb Company, Novartis AG, Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Acceleron Pharma Inc., Ionis Pharmaceuticals Inc., Natco Pharma, Silence Therapeutics plc, Apotex Inc., Cipla Limited, Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, and Teva Pharmaceutical Industries Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global thalassemia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global thalassemia market

Market Segmentation

Type Insights (Revenue, USD Mn, 2020 - 2032)
- Alpha Thalassemia
- Beta Thalassemia
- Delta Thalassemia
- Combination Thalassemia (Mixed Type)
Treatment Type Insights (Revenue, USD Mn, 2020 - 2032)
- Blood Transfusion Therapy
- Iron Chelation Therapy
- Stem Cell Transplantation
- Gene Therapy
- Pharmacotherapy (e.g., Hydroxyurea, Luspatercept)
- Others (Supportive Care)
End User Insights (Revenue, USD Mn, 2020 - 2032)
- Hospitals and Clinics
- Diagnostic Laboratories
- Research and Academic Institutions
- Specialty Treatment Centers
Route of Administration Insights (Revenue, USD Mn, 2020 - 2032)
- Oral
- Parenteral
Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Age Group Insights (Revenue, USD Mn, 2020 - 2032)
- Adult
- Pediatric
- Geriatric
Regional Insights (Revenue, USD Mn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- bluebird bio Inc.
- Bristol Myers Squibb Company
- Novartis AG
- Chiesi Farmaceutici S.p.A.
- Vertex Pharmaceuticals Incorporated
- CRISPR Therapeutics AG
- Acceleron Pharma Inc.
- Ionis Pharmaceuticals Inc.
- Natco Pharma
- Silence Therapeutics plc
- Apotex Inc.
- Cipla Limited
- Sun Pharmaceutical Industries Ltd
- Reddy's Laboratories Ltd
- Teva Pharmaceutical Industries Ltd

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Thalassemia Market, By Type
- Global Thalassemia Market, By Treatment Type
- Global Thalassemia Market, By End User
- Global Thalassemia Market, By Route of Administration
- Global Thalassemia Market, By Distribution Channel
- Global Thalassemia Market, By Age Group
- Global Thalassemia Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Thalassemia Market, By Type, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Alpha Thalassemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Beta Thalassemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Delta Thalassemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Combination Thalassemia (Mixed Type)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Thalassemia Market, By Treatment Type, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Blood Transfusion Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Iron Chelation Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Stem Cell Transplantation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Pharmacotherapy (e.g., Hydroxyurea, Luspatercept)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Others (Supportive Care)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Thalassemia Market, By End User, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Research and Academic Institutions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Specialty Treatment Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Thalassemia Market, By Route of Administration, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Thalassemia Market, By Distribution Channel, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

9. Global Thalassemia Market, By Age Group, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

10. Global Thalassemia Market, By Region, 2020 - 2032, Value (USD Mn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Mn)
  - South Africa
  - North Africa
  - Central Africa

11. Competitive Landscape

bluebird bio Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Chiesi Farmaceutici S.p.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Vertex Pharmaceuticals Incorporated
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
CRISPR Therapeutics AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Acceleron Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Ionis Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Natco Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Silence Therapeutics plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Apotex Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cipla Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sun Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Reddy's Laboratories Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies